No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
Dosimetric characterization and output verification for conical brachytherapy surface applicators. Part I. Electronic brachytherapy source
1. American Cancer Society, Cancer Facts & Figures 2012 (American Cancer Society, Atlanta, 2012).
2. Z. Ouhib and M. Kasper, Clinical Guide to Surface Treatment of Skin Cancer with Brachytherapy (Nucletron, Veenendaal, Netherlands, 2010).
3. D. Granero, J. Pérez-Calatayud, J. Gimeno, F. Ballester, E. Casal, V. Crispín, and R. van der Laarse, “Design and evaluation of a HDR skin applicator with flattening filter,” Med. Phys. 35, 495–503 (2008).
4. J. Pérez-Calatayud, D. Granero, F. Ballester, V. Puchades, E. Casal, A. Soriano, and V. Crispín, “A dosimetric study of Leipzig applicators,” Int. J. Radiat. Oncol., Biol., Phys. 62, 579–584 (2005).
5. M. Evans, M. Yassa, E. Podgorsak, T. Roman, L. Schereiner, and L. Souhami, “Surface applicators for high dose rate brachytherapy in AIDS-related Kaposi's sarcoma,” Int. J. Radiat. Oncol., Biol., Phys. 39, 769–774 (1997).
6.In this paper, certain commercially available products are referred to by name. These references are for informational purposes only and imply neither endorsement by the ADCL nor that these products are the best or only products available for the purpose.
7. M. J. Rivard, S. D. Davis, L. A. DeWerd, T. W. Rusch, and S. Axelrod, “Calculated and measured brachytherapy dosimetry parameters in water for the Xoft Axxent X-Ray Source: An electronic brachytherapy source,” Med. Phys. 33, 4020–4032 (2006).
8. Xoft Inc., Axxent Electronic Brachytherapy System Operator Manual, Appendix J (Xoft Inc., San Jose, CA, 2009).
9. M. J. Rivard, B. M. Coursey, L. A. DeWerd, W. F. Hanson, M. S. Huq, G. S. Ibbott, M. G. Mitch, R. Nath, and J. F. Williamson, “Update of AAPM Task Group No. 43 report: A revised AAPM protocol for brachytherapy dose calculations,” Med. Phys. 31, 633–674 (2004).
10. R. Nath, L. L. Anderson, G. Luxton, K. A. Weaver, J. F. Williamson, and A. S. Megooni, “Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43,” Med. Phys. 22, 209–234 (1995).
11. C.-M. Ma, C. W. Coffey, L. A. DeWerd, C. Liu, R. Nath, S. M. Seltzer, and J. P. Seuntjens, “AAPM protocol for 40–300 kV x-ray beam dosimetry in radiotherapy and radiobiology,” Med. Phys. 28, 868–893 (2001).
12. B. Grosswendt, “Dependence of the photon backscatter factor for water on source-to-phantom distance and irradiation field size,” Phys. Med. Biol. 35, 1233–1245 (1990).
13. B. Grosswendt, “Dependence of the photon backscatter factor for water on irradiation field size and source-to-phantom distance between 1.5 and 10 cm,” Phys. Med. Biol. 38, 305–310 (1993).
15. R. T. Knight and A. E. Nahum, “Depth and field-size dependence of ratios of mass-energy absorption coefficient, water-to-air, for kV X-ray dosimetry,” in Proceedings of the IAEA International Symposium on Measurement Assurance Dosimetry (IAEA, Vienna, 1994), pp. 361–370.
16. J. P. Seuntjens, I. Kawrakow, J. Borg, F. Hobeila, and D. W. O. Rogers, “Calculated and measured air-kerma response of ionization chambers in low- and medium-energy photon beams,” in Recent Developments in Accurate Radiation Dosimetry, AAPM Symposium Proceedings No. 13, edited by J. P. Seuntjens and P. N. Mobit (Medical Physics Publishing, Madison, WI, 2002), pp. 69–84.
17. S. Klevenhagen, R. Aukett, R. Harrison, C. Moretti, A. Nahum, and K. Rosser, “The IPEMB code of practice for the determination of absorbed dose for x-rays below 300 kV generating potential (0.035 mm Al - 4 mm Cu); 10–300 kV generating potential,” Phys. Med. Biol. 41, 2605–2625 (1996).
19. M. C. White, “Photoatomic data library MCPLIB04: A new photoatomic library based on data from ENDF/B-VI Release 8,” Memorandum LA-UR-03-1019, Los Alamos National Laboratory, Los Alamos, NM, 2003.
20. X-5 Monte Carlo Team, MCNP — A General Monte Carlo N-Particle Transport Code, Version 5, Report LA-UR-03-1987, Los Alamos National Laboratory, Los Alamos, NM, 2005.
21. D. Cullen, J. Hubbell, and L. Kissel, “EPDL97: The Evaluated Photon Data Library,” Report UCRL-50400 Vol. 6 Rev. 5, Lawrence Livermore National Laboratory, 1997.
22. K. J. Adams, “Electron upgrade for MCNP4B,” Los Alamos National Laboratory Memorandum X-5-RN(U)-00-14, 2000.
23. K. J. Adams, “Electron Upgrade for MCNP4B,” Memorandum LA-UR-00-3581, Los Alamos National Laboratory, Los Alamos, NM, 2000.
24. I. Kawrakow and D. W. O. Rogers, “The EGSnrc code system: Monte Carlo simulation of electron and photon transport,” Technical Report PIRS-701, National Research Council of Canada, Ottawa, Canada, 2006.
25. S. Davis, “Monte Carlo 101,” Power Point Presentation, University of Wisconsin MRRC Research Meeting, 2009.
26. PTW-Freiburg, Ionization Chamber Type 34013 (PTW-Freiburg, Freiburg, Germany, 1999).
27. T. L. Pike, “A dosimetric Characterization of an electronic brachytherapy source in terms of absorbed dose to water,” Ph.D. dissertation, University of Wisconsin-Madison, 2012.
28. F. H. Attix, Introduction to Radiological Physics and Radiation Dosimetry (John Wiley and Sons, Inc., New York, 1986).
29. J. Snow, J. Micka, and L. DeWerd, “Microionization chamber air-kerma calibration coefficients as a function of photon energy for x-ray spectra in the range of 20 to 250 kVp relative to 60Co,” Med. Phys. 40, 041711 (5pp.) (2013).
30. J. G. Coletti, D. W. Pearson, and L. A. DeWerd, “Mammography exposure standard: Design and characterization of free-air ionization chamber,” Rev. Sci. Instrum. 66, 2574–2577 (1995).
31. Y. Rong and J. S. Welsh, “Surface applicator calibration and commissioning of an electronic brachytherapy system for nonmelanoma skin cancer and treatment,” Med. Phys. 37, 5509–5517 (2010).
34. M. Glecker, J. Valentine, and E. Silberstein, “Calculating lens dose and surface dose rates from Sr-90 opthalmic applicators using Monte Carlo modeling,” Med. Phys. 25(1), 29–36 (1998).
35. A. Angelopoulos, P. Baras, L. Sakelliou, P. Karaiskos, and P. Sandilos, “Monte Carlo dosimetry of a new 192Ir high dose rate brachytherapy source,” Med. Phys. 27(11), 2521–2527 (2000).
36. R. S. Sloboda and G. V. Menon, “Experimental determination of the anisotropy function and anisotropy factor for model 6711 I-125 seeds,” Med. Phys. 27, 1789–1799 (2000).
37. A. S. Meigooni, K. Sowards, and M. Soldano, “Dosimetric characteristics of the InterSource 103Pd brachytherapy source,” Med. Phys. 27, 1093–1100 (2000).
38. A. S. Meigooni, J. A. Meli, and R. Nath, “A comparison of solid phantoms with water for dosimetry of 125I brachytherapy sources,” Med. Phys. 15, 695–701 (1988).
39. J. Dolan, Z. Li, and J. F. Williamson, “Monte Carlo and experimental dosimetry of an 125I brachytherapy seed,” Med. Phys. 33, 4675–4684 (2006).
40. A. Meigooni, S. Awan, N. Thompson, and S. Dini, “Updated Solid WaterTM to water conversion factors for 125I and 103Pd brachytherapy sources,” Med. Phys. 33, 3988–3992 (2006).
42. M. Srinivasan and L. DeWerd, “Effect of plastic deformation on the thermoluminescence of LiF(TLD-100) single crystals,” J. Phys. D: Appl. Phys. Med. Biol. 6, 2142–2143 (1973).
43. A. A. Nunn, S. D. Davis, J. A. Micka, and L. A. DeWerd, “LiF:Mg,Ti TLD response as a function of photon energy for moderately filtered x-ray spectra in the range of 20 to 250 kVp relative to 60Co,” Med. Phys. 35, 1859–1869 (2008).
44. Y. Horowitz and P. Olko, “The effects of ionisation density on the thermoluminescence response (efficiency) of LiF:Mg,Ti and LiF:Mg,Cu,P,” Radiat. Prot. Dosim. 109(4), 331–348 (2004).
45. S. Chiu-Tsao, T. Duckworth, C. Hsiung, Z. Li, J. Williamson, N. Patel, and L. Harrison, “Thermoluminescent dosimetry of the SourceTech Medical model STM1251 125I seed,” Med. Phys. 30, 1732–1735 (2003).
46. J. F. Williamson and M. J. Rivard, “Quantitative dosimetry methods for brachytherapy, brachytherapy physics,” Proceedings of the Joint AAPM/American Brachytherapy Society Summer School (AAPM, College Park, MD, 2006).
47. J. A. Raffi, “Limitations of current dosimetry for intracavitary accelerated partial breast irradiation with high dose rate 192Ir and electronic brachytherapy sources,” Ph.D. dissertation, University of Wisconsin-Madison, 2010.
48. L. DeWerd, L. Bartol, and S. Davis, “Thermoluminescence dosimeters,” Proceedings of the AAPM Summer School (AAPM, College Park, MD, 2009), pp. 815–840.
49. M. S. MacPherson and J. J. Battista, “Dose distributions and dose rate constants for new ytterbium-169 brachytherapy seeds,” Med. Phys. 22, 89–96 (1995).
50. N. S. Patel, S.-T. Chiu-Tsao, J. F. Williamson, P. Fan, T. Duckworth, D. Shasha, and L. B. Harrison, “Thermoluminescent dosimetry of the Symmetra™125I model I25.S06 interstitial brachytherapy seed,” Med. Phys. 28, 1761–1769 (2001).
51. G. Anagnostopoulos, D. Baltas, P. Karaiskos, P. Sandilos, P. Papagiannis, and L. Sakelliou, “Thermoluminescent dosimetry of the selectSeed 125I interstitial brachytherapy seed,” Med. Phys. 29, 709–716 (2002).
53. G. Lymperopoulou, P. Papagiannis, L. Sakelliou, P. Karaiskos, P. Sandilos, A. Przykutta, and D. Baltas, “Monte Carlo and thermoluminescence dosimetry of the new IsoSeed model I25.S17 125I interstitial brachytherapy seed,” Med. Phys. 32, 3313–3317 (2005).
54. S. D. Davis, C. K. Ross, P. N. Mobit, L. Van der Zwan, W. J. Chase, and K. R. Shortt, “The response of LiF thermoluminescence dosemeters to photon beams in the energy range from 30 kV x rays to 60Co gamma rays,” Radiat. Prot. Dosim. 106, 33–43 (2003).
55. B. E. Rasmussen, S. D. Davis, J. A. Micka, and L. A. DeWerd, “Response of LiF:Mg,Ti thermoluminescent dosimeters to low-energy photons,” (abstract) Med. Phys. 35, 2792 (2008).
56. G. M. Mora, A. Maio, and D. W. O. Rogers, “Monte Carlo simulation of a typical 60Co therapy source,” Med. Phys. 26(11), 2494–2502 (1999).
57. R. Kennedy, S. Davis, J. Micka, and L. DeWerd, “Experimental and Monte Carlo determination of the TG-43 dosimetric parameters for the model 9011 THINSeedTM brachytherapy source,” Med. Phys. 37(4), 1681–1688 (2010).
58. T. J. McCaw, J. A. Micka, and L. A. DeWerd, “Characterizing the marker-dye correction for Gafchromic® EBT2 film: A comparison of three analysis methods,” Med. Phys. 38, 5771–5777 (2011).
59. S. Devic, J. Seuntjens, E. Sham, E. B. Podgorsak, C. R. Schmidtlein, A. S. Kirov, and C. G. Soares, “Precise radiochromic film dosimetry using a flat-bed document scanner,” Med. Phys. 32, 2245–2253 (2005).
60. S. Devic, J. Seuntjens, G. Hegyi, E. Podgorsak, C. G. Soares, A. S. Kirov, I. Ali, J. F. Williamson, and A. Elizondo, “Dosimetric properties of improved GafChromic films for seven different digitizers,” Med. Phys. 31, 2392–2401 (2004).
61. S. Devic, J. Seuntjens, W. Abdel-Rahman, M. Evans, M. Olivares, E. B. Podgorsak, T. Vuong, and C. G. Soares, “Accurate skin dose measurements using radiochromic film in clinical applications,” Med. Phys. 33, 1116–1124 (2006).
62. S. Devic, S. Aldelaijan, H. Mohammed, N. Tomic, L. Liang, F. Deblois, and J. Seuntjens, “Absorption spectra time evolution of EBT-2 model GAFCHROMIC™ film,” Med. Phys. 37, 2207–2214 (2010).
63. S. Devic, N. Tomic, S. Aldelaijan, F. DeBlois, J. Seuntjens, M. F. Chan, and D. Lewis, “Linearization of dose–response curve of the radiochromic film dosimetry system,” Med. Phys. 39(8), 4850–4857 (2012).
64. B. Arjomandy, R. Tailor, N. Sahoo, M. Gillin, K. Prado, and M. Vicic, “Energy dependence and dose response of GafChromic EBT2 film over a wide range of photon, electron, and proton beam energies,” Med. Phys. 37, 1942–1947 (2010).
65. L. Richley, A. C. John, H. Coomber, and S. Fletcher, “Evaluation and optimization of the new EBT2 radiochromic film dosimetry system for patient dose verification in radiotherapy,” Phys. Med. Biol. 55, 2601–2617 (2010).
66. A. Niroomand-Rad, C. R. Blackwell, B. M. Coursey, K. P. Gall, J. M. Galvin, W. L. McLaughlin, A. S. Meigooni, R. Nath, J. E. Rodgers, and C. G. Soares, “Radiochromic film dosimetry: Recommendations of AAPM Radiation Therapy Committee Task Group 55,” Med. Phys. 25, 2093–2115 (1998).
67. UWRCL, UW-RCL Quality Manual I.3.3 Uncertainty Tables: Air Kerma Therapy (UWADCL, Madison, WI, 2008).
68. S. D. Davis, “Air-kerma strength determination of a miniature x-ray source for brachytherapy applications,” Ph.D. dissertation, University of Wisconsin–Madison, 2009.
69. S. Nag, D. Beyer, J. Friedland, P. Grimm, and R. Nath, “American brachytherapy society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer,” Int. J. Radiat. Oncol., Biol., Phys. 44(4), 789–799 (1999).
70. L. Bartol and L. DeWerd, “Characterization of thermoluminescent dosimeter reader precision and artifacts,” (abstract) Med. Phys. 35, 2796 (2008).
71. UWRCL, UW-RCL Quality Manual I.5.1 Uncertainty Tables: Diagnostic TLD (UWADCL, Madison, WI, 2008).
Article metrics loading...
Historically, treatment of malignant surface lesions has been achieved with linear accelerator based electron beams or superficial x-ray beams. Recent developments in the field of brachytherapy now allow for the treatment of surface lesions with specialized conical applicators placed directly on the lesion. Applicators are available for use with high dose rate (HDR)192Ir sources, as well as electronic brachytherapy sources. Part I of this paper will discuss the applicators used with electronic brachytherapy sources; Part II will discuss those used with HDR 192Ir sources. Although the use of these applicators has gained in popularity, the dosimetric characteristics including depth dose and surface dose distributions have not been independently verified. Additionally, there is no recognized method of output verification for quality assurance procedures with applicators like these. Existing dosimetry protocols available from the AAPM bookend the cross-over characteristics of a traditional brachytherapy source (as described by Task Group 43) being implemented as a low-energy superficial x-ray beam (as described by Task Group 61) as observed with the surface applicators of interest.
This work aims to create a cohesive method of output verification that can be used to determine the dose at the treatment surface as part of a quality assurance/commissioning process for surface applicators used with HDR electronic brachytherapy sources (Part I) and192Ir sources (Part II). Air-kerma rate measurements for the electronic brachytherapy sources were completed with an Attix Free-Air Chamber, as well as several models of small-volume ionization chambers to obtain an air-kerma rate at the treatment surface for each applicator. Correction factors were calculated using MCNP5 and EGSnrc Monte Carlo codes in order to determine an applicator-specific absorbed dose to water at the treatment surface from the measured air-kerma rate. Additionally, relative dose measurements of the surface dose distributions and characteristic depth dose curves were completed in-phantom.
Theoretical dose distributions and depth dose curves were generated for each applicator and agreed well with the measured values. A method of output verification was created that allows users to determine the applicator-specific dose to water at the treatment surface based on a measured air-kerma rate.
The novel output verification methods described in this work will reduce uncertainties in dose delivery for treatments with these kinds of surface applicators, ultimately improving patient care.
Full text loading...
Most read this month